Molecular Interactions between NAFLD and Xenobiotic Metabolism
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, is a complex multifactorial disease characterized by metabolic deregulations that include accumulation of lipids in the liver, lipotoxicity, and insulin resistance. The progression of NAFLD to non-alcoholic steatohepatitis and cirrhosis, and ultimately to carcinomas, is governed by interplay of pro-inflammatory pathways, oxidative stress, as well as fibrogenic and apoptotic cues. As the liver is the major organ of biotransformation, deregulations in hepatic signaling pathways have effects on both, xenobiotic and endobiotic metabolism. Several major nuclear receptors involved in the transcription and regulation of phase I and II drug metabolizing enzymes and transporters also have endobiotic ligands including several lipids. Hence, hepatic lipid accumulation in steatosis and NAFLD, which leads to deregulated activation patterns of nuclear receptors, may result in altered drug metabolism capacity in NAFLD patients. On the other hand, genetic and association studies have indicated that a malfunction in drug metabolism can affect the prevalence and severity of NAFLD. This review focuses on the complex interplay between NAFLD pathogenesis and drug metabolism. A better understanding of these relationships is a prerequisite for developing improved drug dosing algorithms for the pharmacotherapy of patients with different stages of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“REVIEW ARTICLE published: 22 January 2013 doi: 10.3389/fgene.2013.00002 Molecular interactions between NAFLD and xenobiotic metabolism”
BackgroundInfluentialInflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435 · cited 2×
“…2001; Browning and Horton, 2004; Wree et al., 2011), the interaction of the intestinal microbial populations with the host through the inflammasome (Henao-Mejia et al., 2012), downregulation of the endoplasmic reticulum stress and protein ubiquitination pathways (HSPA5, USP25), and gene expression…”
BackgroundHuman Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089 · cited 1×
“NAFLD is the hepatic manifestation of the metabolic syndrome as it is frequently associated with obesity, insulin resistance, hyperglycemia, hypertension, and dyslipidemia (Anderson and Borlak, 2008; Lewis and Mohanty, 2010; Cohen et al., 2011).”
BackgroundMolecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772 · cited 4×
“…the progression of NAFLD to NASH was described as a two-hit event, with the accumulation of hepatic triglycerides being the first hit, which in turn triggers the second hit – inflammation and oxidative stress (Crespo et al., 2001; Browning and Horton, 2004; Sunny et al., 2011; Wree et al., 2011).”
BackgroundInfluentialPeroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 2×
“Since rosiglitazone is used in NAFLD patients with hyperglycemia and IR (Ratziu et al., 2008), patients with PXR”
MethodLeite, N. C., Salles, G. F., Araujo, A. L. E., Villela‐Nogueira, C. A., & Cardoso, C. R. L. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01718.x · Cited by 531
Central Role of Pparα–Dependent Hepatic Lipid Turnover in Dietary Steatohepatitis in Mice
Ip, E., Farrell, G. C., Robertson, G., Hall, P., Kirsch, R., & Leclercq, I. (2003) · Hepatology · doi:10.1053/jhep.2003.50307 · Cited by 476 · cited 2×
“…Busulfan (anti-cancer) Cyclophosphamide (anti-cancer) GSTM2, GSTM4, and GSTM5 mRNA levels decreased in patients with steatosis and NASH (Ip et al., 2003) Overall GST activity decreased with disease progression, accompanied by a reduced pool of glutathione, highlighting the depleted…”
BackgroundEnhanced free cholesterol, SREBP-2 and StAR expression in human NASH
Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.016 · Cited by 368
Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects
di Masi, A., Marinis, E. D., Ascenzi, P., & Marino, M. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.002 · Cited by 288 · cited 1×
“Apart from being activated by xenobiotics, it also responds to endobiotics including bile acids (Xie et al., 2001) and steroid hormones (di Masi et al., 2009).”
BackgroundLiver-specific Deletion of the NADPH-Cytochrome P450 Reductase Gene
Gu, J., Weng, Y., Zhang, Q.-Y., Cui, H., Behr, M., Wu, L., Yang, W., Zhang, L., & Ding, X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303125200 · Cited by 214 · cited 1×
“The liver conditional Por knockout mice display hepatomegaly, hepatic steatosis, and a reduced capacity of drug metabolism (Gu et al., 2003).”
BackgroundMitsuyoshi, H., Yasui, K., Harano, Y., Endo, M., Tsuji, K., Minami, M., Itoh, Y., Okanoue, T., & Yoshikawa, T. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00464.x · Cited by 172 · cited 2×
“Other groups have also previously indicated decreased CYP2E1 mRNA and protein levels and no changes in CYP2E1 activity at progressive stages of NAFLD (Fisher et al., 2009b; Mitsuyoshi et al., 2009).”
BackgroundLake, A. D., Novak, P., Fisher, C. D., Jackson, J. P., Hardwick, R. N., Billheimer, D. D., Klimecki, W. T., & Cherrington, N. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040592 · Cited by 167 · cited 2×
“The expression of these transporters is significantly altered in the transition from steatosis to NASH rather than between control and steatotic samples (Fisher et al., 2009a; Lake et al., 2011).”
BackgroundFirneisz, G., Varga, T., Lengyel, G., Fehér, J., Ghyczy, D., Wichmann, B., Selmeci, L., Tulassay, Z., Rácz, K., & Somogyi, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012226 · Cited by 121 · cited 1×
“T2D patients with NAFLD have increased serum DPP-4 activity, an enzyme that inhibits incretins such as glucagon-like peptide 1 (GLP-1), and thus, reduced efficacy of sitagliptin (Firneisz et al., 2010; Iwasaki et al., 2012).”
BackgroundKeber, R., Motaln, H., Wagner, K. D., Debeljak, N., Rassoulzadegan, M., Ačimovič, J., Rozman, D., & Horvat, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.253245 · Cited by 102
Self-citationMAREK, C. J., TUCKER, S. J., KONSTANTINOU, D. K., ELRICK, L. J., HAEFNER, D., SIGALAS, C., MURRAY, G. I., GOODWIN, B., & WRIGHT, M. C. (2005) · Biochemical Journal · doi:10.1042/bj20041598 · Cited by 89 · cited 1×
“In support of the previous statement, rats treated with a PXR activator pregnenolone-16α-carbonitrile (PCN) displayed reduced hepatic fibrosis and necrosis in response to a fibrogenesisinducing agent carbon tetrachloride (CCl4; Marek et al., 2005).”
MethodGeier, A., Dietrich, C. G., Grote, T., Beuers, U., Prüfer, T., Fraunberger, P., Matern, S., Gartung, C., Gerbes, A. L., & Bilzer, M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.031 · Cited by 66 · cited 2×
“…models of obesity, NAFLD and NASH and normalized on roziglitazone treatment (Lin et al., 2009) rs17222723 and rs8187710 variants in the ABCC2 are significantly associated with NAFLD patients and clinical and histological parameters (Geier et al., 2005; Fisher et al., 2009a; Martin et al., 2010)”
Background
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“Available data show moderately reduced expression for most but not all CYP1-3 enzymes (Naik et al., 2013).”
BackgroundSelf-citationCobbina, E., & Akhlaghi, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1293683 · Cited by 653
Nuclear receptors and nonalcoholic fatty liver disease
Cave, M. C., Clair, H. B., Hardesty, J. E., Falkner, K. C., Feng, W., Clark, B. J., Sidey, J., Shi, H., Aqel, B. A., McClain, C. J., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.03.002 · Cited by 279
Bessone, F., Dirchwolf, M., Rodil, M. A., Razori, M. V., & Roma, M. G. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14952 · Cited by 102
Wang, X., Li, Q., Pang, J., Lin, J., Liu, Y., Xu, Z., Zhang, H., Shen, T., Chen, X., Ma, J., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.007 · Cited by 11
Metadata
- Authors
- Naik, A., Belič, A., Zanger, U. M., & Rozman, D.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 2-2
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2023841187
- Cited by
- 72
- References
- 19
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.